Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

This Company is Leading Future of Psychedelic Medicine

Jocelyn Aspa Jocelyn Aspa, The Market Herald
2 Comments| March 23, 2022

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlargeThe use of psychedelics is continuing to rise at a rapid rate as a method of treatment for mental health conditions. As ailments such as depression and anxiety continue rising, psychedelic treatments continue to prove their effectiveness in these areas as well as for PTSD and chronic pain.

Case in point, research shows that psychedelic therapy has given 80% of people who have taken psychedelics a positive outcome compared to patients who have taken a placebo. When it comes to the overall market's growth, moving forward it is estimated that the psychedelics drug market will grow at a compound annual growth rate of 13.3% between 2022 and 2029 to reach US$75.52 billion fueled by the rising prevalence of depression and anxiety as well as the availability of off-label drugs such as psychedelics.

Companies like Cube Psytech company are at the forefront of this growing market thanks to its psilocybin and psilocin brain receptor solutions. Founded in January 2021, Vancouver, BC-based Cube Psytech's solutions are designed to create innovative psilocybin and psilocin drugs and protocols for clinical trials and patient-prescribed uses at a global scale.


Cube Psytech's solutions

Because Cube Psytech's team has identified psilocybin and psilocin brain receptor solutions that can be applied to its leading and pre-existing Neurobiology patents, the company sees this as a competitive advantage to fast-track its related research and development plan in order to develop psilocybin and psilocin drugs for clinical trials and patient-prescribed uses.

As such, the company aims to treat with its psilocybin-assisted psychotherapy and through clinical studies cancer-related psychiatric distress, addiction, treatment-resistant depression, obsessive compulsive disorder, cluster headaches.
On that note, the company's solutions include the psilocybin assisted psychotherapy and artificial intelligence assisted psychotherapy. At present, the company filing over 10 patents to its name.

Those patents will be focused on patent protocols, which the company said is "a system to therapy with psilocybin," but also with VR therapy and bio-markers that show the analytics of depression before taking psilocybin or any treatment.
Under the Cube Psytech Corp. division, the company has two applications with Health Canada right now, including an Exemption 56J License (a request for clinical trials with psilocybin) and a Dealer's License with Health Canada. Both are currently in the review period which, once approved, will allow the company to conduct advanced research, control studies, cultivate, manufacture, and distribute its pharmaceutical-grade psilocybin products.

The patent Accessibility for the innovative psychedelic technologies includes:
  • Neurobiology patents that can be used to further psilocybin and psilocin molecules interactions with brain receptors.
  • Use of nanotechnology in psilocybin as a drug molecule to treat chronic stress generated by cancer.
  • Patented technology to optimize controlled environment to modify the efficiency of eukaryotic cells which includes fungus / mycelium.


Cube Psytech's products

The company's line of non-psychoactive products features formulations that include healthy functional mushrooms and supportive compounds meant to target modern health issues. Cube Psytech's products are all Non-GMO, FDA-compliant, drug-free and gluten and allergen free, free of artificial colors, flavors, preservatives, and made with organic ingredients. At present, Cube Psytech has five proprietary formulas approved for sale in Canada and the USA.

  • Elevate
  • Longevity
  • Stress
  • Recovery
  • Focus

The company’s products are formulated from proven adaptogens used in traditional and western health remedies including medicinal mushrooms. The products will be available on Amazon and on Shopify. Cube Psytech is working with top design and marketing agencies to bring their revolutionary products to market. Cube Psytech’s products sell under the banner Cube Labs.


Why invest?

Although not yet public, the company is backed by a world class drug delivery and formulation as well as a research and development science team.

Cube Psytech also has accessibility for over 10 patents on precision drug delivery systems and access to 1,902 total publications on psychedelics with 1,239 of them on psilocybin.

The company also has plans for a dual listing on the Canadian Securities Exchange and the OTC Markets and has proven capital markets experience, land and building assets and a functional mushroom line.


Here's the deal

Cube Psytech company is raising up to C$2 million thorough a private placement. The financing will consist of a combination of up to 8,000,000 units at a price of $0.25 per unit and ½ warrant at $0.40.

There is no minimum placement amount, and the company may close the placement in one or more tranches. The company will use the net proceeds of the offering as follows: to fund the company's continuing development, and for general working capital purposes.

Each unit consists of one common share in the capital of the company (the "Common Shares") and one half of one (1/2) Common Share purchase warrant of the company (the "Warrants"), with each Warrant entitling the holder thereof to acquire one Common Share (a "Warrant Share") at an exercise price of $0.40 per Warrant Share for a period of three years following the Closing Date (as defined herein), subject to adjustment in certain events. The Warrants are subject to early acceleration in the event that the company's common shares have a closing price on any nationally recognized stock exchange of greater than $0.80 per share for a period of 20 consecutive trading days, at which time the company may accelerate the expiry date of the Warrants by giving notice to the holders thereof and, in such case, the Warrants will expire on the 30th day after the date on which such notice is given to the holder by the company.


Highlights

  • Up to 8,000,000 units at a price of $0.25 per unit and ½ warrant at $0.40.
  • Gross proceeds of up to $2 million
  • Proceeds will be used to fund the company's continued development and general working capital purposes

The Stockhouse DealRoom: your destination to participate in exclusive financings, featuring some of the most innovative companies and best deals currently available on the market. To sign up below and to receive materials related to participating in the current financing, click here: View the Cube Psytech Corporation DealRoom Private Placement here for full details on its current financing opportunity.


FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today